Skip to main content
. 2007 May 25;6(4):168–399. doi: 10.1111/j.1524-6175.2006.03304.x

Figure 4.

Figure 4

Reductions in blood pressure (BP). Patients who were treated for 8 weeks with olmesartan medoxomil alone (n=198) had a mean reduction in seated diastolic BP (SeDBP) from 96.6 mm Hg (baseline) to 85.9 mm Hg (−10.7 mm Hg), and a mean reduction in seated systolic BP (SeSBP) from 161.2 mm Hg (baseline) to 143.5 mm Hg (−17.7 mm Hg). At Week 16, after an additional 8 weeks of combination therapy for patients who did not achieve BP goal at Week 8 (n=123), mean BP was decreased an additional increment of −11.61–5.4 mm Hg relative to monotherapy. The mean BP reduction among patients who received all three antihypertensive medications (olmesartan medoxomil + hydrochlorothiazide [HCTZ] + amlodipine) (n=49) was −33.7/−18.2 mm Hg, an additional −4.4/−2.1 mm Hg, compared with two‐drug combination therapy.